WO2023114529A3 - Pharmacoactive formulations for delivery of psychedelic compounds - Google Patents

Pharmacoactive formulations for delivery of psychedelic compounds Download PDF

Info

Publication number
WO2023114529A3
WO2023114529A3 PCT/US2022/053291 US2022053291W WO2023114529A3 WO 2023114529 A3 WO2023114529 A3 WO 2023114529A3 US 2022053291 W US2022053291 W US 2022053291W WO 2023114529 A3 WO2023114529 A3 WO 2023114529A3
Authority
WO
WIPO (PCT)
Prior art keywords
psychedelic
delivery
pharmacoactive
formulations
compounds
Prior art date
Application number
PCT/US2022/053291
Other languages
French (fr)
Other versions
WO2023114529A2 (en
Inventor
Jerry B. Gin
Benjamin F. Ross
Original Assignee
Bennes, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bennes, Inc. filed Critical Bennes, Inc.
Publication of WO2023114529A2 publication Critical patent/WO2023114529A2/en
Publication of WO2023114529A3 publication Critical patent/WO2023114529A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Abstract

Lozenges comprising ethyl cellulose and psychedelic compound s for rapid and efficient delivery of medical psychedelic compound s are provided. The lozenge is suitable for administration of the psychedelic compound (s) through the oral mucosa to the bloodstream. Embodiments of the lozenge are disclosed that comprise additives which alleviate other issues related to administration of psychedelic compounds. Additives disclosed include essential oils for flavoring, permeation enhancers, and high-intensity sweeteners. Methods for manufacture of the lozenges and its use in treatment of disease conditions are provided.
PCT/US2022/053291 2021-12-17 2022-12-17 Pharmacoactive formulations for delivery of psychedelic compounds WO2023114529A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163291333P 2021-12-17 2021-12-17
US63/291,333 2021-12-17

Publications (2)

Publication Number Publication Date
WO2023114529A2 WO2023114529A2 (en) 2023-06-22
WO2023114529A3 true WO2023114529A3 (en) 2023-10-26

Family

ID=86773427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/053291 WO2023114529A2 (en) 2021-12-17 2022-12-17 Pharmacoactive formulations for delivery of psychedelic compounds

Country Status (1)

Country Link
WO (1) WO2023114529A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089863A1 (en) * 2016-11-11 2018-05-17 Bennes, Inc. Formulations for efficient delivery of cannabinoids
US20210145851A1 (en) * 2019-11-19 2021-05-20 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089863A1 (en) * 2016-11-11 2018-05-17 Bennes, Inc. Formulations for efficient delivery of cannabinoids
US20210145851A1 (en) * 2019-11-19 2021-05-20 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DESCALÇO N., MEDEIROS A.B., SANTOS C. FERNANDES, BORGES G.: "Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far?", EUROPEAN PSYCHIATRY, vol. 64, no. S1, 13 August 2021 (2021-08-13), FR , pages S417 - S417, XP093103742, ISSN: 0924-9338, DOI: 10.1192/j.eurpsy.2021.1114 *
MACCALLUM CAROLINE A., EADIE LAUREN, BARR ALASDAIR M., BOIVIN MICHAEL, LU SHAOHUA: "Practical Strategies Using Medical Cannabis to Reduce Harms Associated With Long Term Opioid Use in Chronic Pain", FRONTIERS IN PHARMACOLOGY, vol. 12, 1 January 2021 (2021-01-01), pages 1 - 9, XP093103747, DOI: 10.3389/fphar.2021.633168 *
WELTMAN A. S., SACKLER A. M., PANDHI V., JOHNSON L.: "Behavior and endocrine effects of 3,4,5-trimethoxyamphetamine in male mice", EXPERIENTIA, vol. 32, no. 3, 1 March 1976 (1976-03-01), CH , pages 357 - 359, XP009549934, ISSN: 0014-4754, DOI: 10.1007/BF01940837 *

Also Published As

Publication number Publication date
WO2023114529A2 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
JP5693455B2 (en) Treatment of inflammation and inflammatory pain in the mucosa using a carrier for treatment of long-term mucosal release bioadhesion
US20100215776A1 (en) Method of treating a sore throat
JP4669960B2 (en) Oral or pharyngeal preparations containing local anesthetics
JPWO2012029913A1 (en) Oral
JP2004161667A (en) Crude drug-formulated pharmaceutical composition
JP5337430B2 (en) Orally disintegrating tablets
WO2023114529A3 (en) Pharmacoactive formulations for delivery of psychedelic compounds
US20060251731A1 (en) Therapeutic herbal lozenge composition
RU2426529C2 (en) Orally decomposing powder, containing cilostazol and mannitol
EP0225831B1 (en) Use of hyperoxygenated oils for the manufacture of a medicament for the treatment of herpes
JP6324951B2 (en) Drugs for dysphagia
EP1694295B1 (en) Pharmaceutical oral dosage form comprising a non-steroidal anti-inflammatory drug, and having good palatability
JP7123205B2 (en) Oral pharmaceutical composition
CA2444839A1 (en) Ambroxol for the treatment of inflammation in the pharynx
EP1646373B1 (en) Orodispersible pharmaceutical composition of an antithrombotic compound
RU2782018C1 (en) Remedy for those quitting smoking
RU2253442C1 (en) Cheek pouch (transbuccal) pharmaceutical composition
JP2005162713A (en) Composition for oral administration
WO2024097327A1 (en) Cannabinoid formulations and use for treatment of emotional disorders and sexual dysfunction
RU2216320C1 (en) Agent "faringal" for prophylaxis and treatment of infectious- inflammatory disease of mouth-pharynx
EP2018868A1 (en) Compositions for the treatment and prevention of vertigo and tinnitus including citicoline, ginkgo biloba extract and dimeric flavones of ginkgo biloba
Nogueira et al. 44265 Oral coenzyme Q10: the new authority in skin aging. Results of a randomized, double-blind, placebo-controlled trial in elderly women
WO2023096535A1 (en) Smoking cessation agent
Choi et al. 44146 Oral Ruxolitinib Treatment for Patients With Dermatologic Manifestations of Acute or Chronic Graft-Versus-Host Disease (GVHD): A Post Hoc Analysis of the Phase 3 REACH2 and REACH3 Studies
RU2537034C1 (en) Therapeutic agent for oral cleaning in individuals suffering xerostomia, possessing antiseptic action as spray, gel and mouthwash

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22908523

Country of ref document: EP

Kind code of ref document: A2